A Randomized Double-Blind Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.

Tung-Ping SuCheng-Ta LiWei-Chen LinHui-Ju WuShih-Jen TsaiYa-Mei BaiWei-Chung MaoPei-Chi TuLi-Fen ChenWei-Chi LiMu-Hong Chen

Published in: The international journal of neuropsychopharmacology (2023)

Low-dose ketamine infusion is a safe, tolerable, and effective treatment for patients with TRD and prominent suicidal ideation. Our study highlights the importance of timing; specifically, ketamine is more likely to achieve therapeutic response when the current depressive episode lasted for <24 months and the number of failed antidepressants is ≤4.

Keyphrases

low dose
double blind
pain management
high dose
clinical trial
bipolar disorder
study protocol
placebo controlled
major depressive disorder
open label
depressive symptoms
stress induced
phase iii
sleep quality
phase ii
chronic pain
replacement therapy
smoking cessation